New drug combo aims to shrink breast tumors before surgery
NCT ID NCT07305246
First seen Jan 07, 2026 · Last updated May 07, 2026 · Updated 14 times
Summary
This study tests a new drug called SHR-A1811, given alone or with hormone therapy (letrozole), before surgery for early-stage breast cancer that is hormone-receptor-positive and HER2-low. About 120 women will be randomly assigned to one of three groups: the new drug plus hormone therapy, the new drug alone, or standard chemotherapy. The goal is to see if the new approach works better at eliminating cancer in the breast and lymph nodes at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.